EUVIMED · CrossrefJournal
Breast Cancer Research and Treatment
ISSN 0167-6806 · Springer Science and Business Media LLC
Latest articles
Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
Association between screen-detected health-related social needs and nonadherence to endocrine therapy in patients with nonmetastatic breast cancer: an observational study
A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic
Clinicopathological differences between asymptomatic vs symptomatic breast cancer: a 30-year single-center retrospective study
Brain as a site of first recurrence after adjuvant therapy for early breast cancer: mining the hellenic cooperative oncology group database-The BRACE study
Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial
Survival benefit of adding carboplatin to standard anthracycline–taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis
Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence
Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India
Sociodemographic and clinicopathologic features associated with rapid relapse in triple-negative breast cancer: a Swedish nationwide registry-based study
Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials
Effects of digital stress-management interventions in breast cancer patients 18 months after intervention access
Venous thromboembolism after breast cancer surgery: incidence, predictive factors and outcomes in 270,564 patients
Acceptability of a patient support and educational intervention for black breast cancer survivors
The landscape of cell surface target expression in treatment resistant early-stage breast cancer
Chemoendocrine therapy versus tamoxifen with ovarian function suppression in women with node-positive breast cancer
Computed tomography derived cardiometabolic biomarkers in high-risk breast cancer using fully automated deep learning algorithms
Adjuvant chemotherapy and overall survival in premenopausal women with HR+/HER2 − early breast cancer: a national cancer database analysis in the era of genomic testing and CDK4/6 inhibitors
Co-payments and adherence to endocrine therapy among Medicaid beneficiaries with breast cancer
Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study
Updated insights into breast cancer survival disparities by race/ethnicity and HR/HER2 molecular subtypes: a Florida population-based analysis
Circulating miR-125b-5p and miR-210-3p are reduced in long-term breast cancer survivors with cardiovascular disease
Real-world patient experiences in HR+/HER2- metastatic breast cancer: a study of symptom and side effect reporting by patients and physicians
Retraction Note: Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer
Rechallenge, switch, or target? navigating advanced breast cancer after adjuvant CDK 4/6 inhibitors
Trends in the use of radiation therapy for second primary breast cancer
SERENA-6 and the regulatory limits of radiologic progression in modern oncology
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
Correction: Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients—a prospective study
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study
Volumes
2026 · 3002025 · 3552024 · 3732023 · 3352022 · 3682021 · 4742020 · 4752019 · 4732018 · 4742017 · 4532016 · 3702015 · 4382014 · 4262013 · 4622012 · 6882011 · 6442010 · 5962009 · 4432008 · 3542007 · 2832006 · 2512005 · 2452004 · 2032003 · 2672002 · 2162001 · 1842000 · 1621999 · 1751998 · 1791997 · 1361996 · 1661995 · 1251994 · 1421993 · 1411992 · 1101991 · 1311990 · 891989 · 681988 · 791987 · 69
EUVIMED